What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
David Liew drdavidliew
3 years 4 months ago
Sometimes the journey impacts as much as the destination.
TREAT-EARLIER now @TheLancet:
pre-RA (CSA+MRI)
DBRCT: po MTX for 1y (+im mpred120x1) vs placebo
eventual RA same
but persistent benefit at 2y (1y post-MTX cessation):
function, Sx, presenteeism, MRI
a short thread🧵1/7 https://t.co/64b7us6hvS
Dr. John Cush RheumNow
3 years 4 months ago
During 2021-22, there was 387,112 deaths due to pneumonia, influenza, or COVID-19. At least 72% were dut to COVID-19 and 0.6% was due to influenza https://t.co/0ljpXJt0yr https://t.co/1Sp4RULVAY
Dr. John Cush RheumNow
3 years 4 months ago
Sign up for Tuesday Night Rheumatology at 7pm!
https://t.co/MLI4MW7eRW https://t.co/xGln5QN8kp
Are you treating “systemic” or “articular” (arthritis) Still’s disease? Most Still’s patients have a dominance of one or the other. With certainty, the right therapy for the right symptoms can be chosen. What about patients who have an incomplete or no response, or who become unresponsive to a drug that once worked well?
Dr. John Cush RheumNow
3 years 4 months ago
Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/QUTIbK3r89 https://t.co/FZcTLREida
Dr. Jack Cush covers the news and journal reports from the past week on RheumNow.com. This week we have Insights NAFLD, overdose deaths, septic arthritis, refractory stills, & when MTX doesn’t work.
Dr. John Cush RheumNow
3 years 5 months ago
The Still’s Continua The concept of a “Still’s disease continuum” that encompasses both sJIA and AOSD is based on the many common clinical, genetic and laboratory features shared by both sJIA and AOSD. https://t.co/XvtzGBX4MS https://t.co/WJC8U9JNXO
Dr. John Cush RheumNow
3 years 5 months ago
NHANES Cross-sectional study of 5672 psoriasis US adults (20-59 yrs) shows more NAFLD in PSO patients (33% vs 27% nonPSO) with an increased risk (OR 1.67) - moreso in men (OR 2.16), age 20-39 yrs (OR 2.48) & those without diabetes (OR 1.70) https://t.co/VfaJbMKboP https://t.co/dJlcLexDtn
Patients and their family for years have been inviting me to their dinners, picnics, baptisms, anniversaries, and funerals. I always felt somewhat awkward when asked to participate in a patient’s life outside of my office or the hospital setting and usually will decline politely. I tell myself I should not blur the lines between patient care and friendship.
I broke this rule recently.
Dr. John Cush RheumNow
3 years 5 months ago
Rheumatologist Survey:
What do you rely on MOST in diagnosing Still’s disease?
Sxs? Labs? Both? Criteria? Fever?
Vote here:
https://t.co/oANKpKqJA5 https://t.co/LIjRSBHNBi
Dr. John Cush RheumNow
3 years 5 months ago
Overdose deaths increased to 107 000 deaths in US in 2021, with significant racial disparity. Higher overdose rates seen in American Indian, Alaska Natives and Blacks. WORSE during COVID - 2020, overdose rates were 7 times higher in Blacks than Whites https://t.co/kuXmskZKbB https://t.co/jPkIYrMnSN
Dr. John Cush RheumNow
3 years 5 months ago
Metanalysis of 9 studies (RCTs, observational) looked @ DMARD effect (most Rx w/ biologics: TNFi, TCZ, RTX, Tofa) on lean & appendicular mass; shows despite bDMARD efficacy - no change in muscle mass! How will UR pts get STRONG? https://t.co/L7bRzPy02i https://t.co/gm5UZYOOeC
Dr. John Cush RheumNow
3 years 5 months ago
2015 NEJM study of 4g acetaminophen vs PBO in 700 critically ill ICU patients with fever ≥38°C, showed Tylenol vs PBO had no differences in mortality, ICU stay or LFTs. Tylenol had small but signif reduction in Temp (38.4±1.0°C vs. 38.6±0.8°C; P<0.001) https://t.co/qnHgFRp20M https://t.co/2E4ZEsIFUV
Poster Hall